Carboplatin
Extensive Disease
Danish Oncological Lung Cancer GroupSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Extensive Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Danish Oncological Lung Cancer Group | Phase 3 | B |
Hycamtin Danish Oncological Lung Cancer Group | Phase 3 | B |
ETOPOSIDE Danish Oncological Lung Cancer Group | Phase 3 | B |
TAMOXIFEN Institut Cancerologie de l'Ouest | Phase 2 | CCC |
Arimidex Institut Cancerologie de l'Ouest | Phase 2 | CCC |
Same molecule, other indications
Carboplatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →